Kennedy Capital Management, Inc. Affimed N.V. Transaction History

Kennedy Capital Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.32 - $0.62 $202,316 - $391,988	632,240 New	632,240 $391,000
Q4 2022 Feb 14, 2023	SELL	$1.1 - $2.45 $19 - $44	-18 Reduced 0.01%	121,787 $151,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $103,056 - $174,565	52,580 Added 75.96%	121,805 $251,000
Q2 2022 Aug 10, 2022	SELL	$2.27 - $4.86 $1,505 - $3,222	-663 Reduced 0.95%	69,225 $192,000
Q1 2022 May 16, 2022	SELL	$3.69 - $5.65 $39,800 - $60,940	-10,786 Reduced 13.37%	69,888 $305,000
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $433,219 - $570,365	80,674 New	80,674 $445,000
Q2 2018 Aug 14, 2018	SELL	$1.65 - $2.5 $1.22 Million - $1.85 Million	-740,783 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$1.25 - $2.65 $925,978 - $1.96 Million	740,783 New	740,783 $1.37 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.